Vista Pharmaceuticals Ltd

Vista Pharmaceuticals Ltd has reached a new 52-week low price of Rs.6.57, marking a significant decline amid ongoing financial pressures and subdued market performance within the Pharmaceuticals & Biotechnology sector.

Vista Pharmaceuticals Ltd’s stock touched a new 52-week low of Rs.7 today, marking a significant decline amid persistent downward momentum. The stock has underperformed its sector and broader market indices, reflecting ongoing financial pressures and subdued performance metrics.

Vista Pharmaceuticals Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 18 July 2024, but the analysis below reflects the stock’s current position as of 26 January 2026, incorporating the latest fundamentals, returns, and financial metrics available today.

Vista Pharmaceuticals Ltd touched a new 52-week low of Rs.7.61 today, marking a significant decline in its share price amid a broader market downturn and persistent company-specific headwinds.

Vista Pharmaceuticals Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 18 Jul 2024, reflecting a significant reassessment of the stock’s outlook. However, the analysis and financial data presented here are based on the company’s current position as of 25 December 2025, providing investors with the latest insights into its performance and prospects.

Vista Pharma., a microcap player in the Pharmaceuticals & Biotechnology sector, has experienced a revision in its market evaluation reflecting ongoing challenges in its financial and operational performance. The recent assessment highlights concerns across multiple parameters including quality, valuation, financial trends, and technical outlook, underscoring the stock's current position within a difficult market environment.

Vista Pharmaceuticals Ltd witnessed an exceptional surge in buying interest on 19 Nov 2025, hitting the upper circuit with only buy orders in the queue. The stock recorded a remarkable 20.00% gain in a single trading session, significantly outperforming the Sensex’s modest 0.33% rise, signalling a potential multi-day circuit scenario driven by extraordinary demand and absence of sellers.

Vista Pharmaceuticals has reached a new 52-week low of Rs.7.63 today, marking a significant decline in its stock price amid ongoing downward momentum. The stock has underperformed its sector and broader market indices, reflecting persistent challenges in its financial performance and valuation metrics.

Vista Pharmaceuticals has reached a new 52-week low of Rs. 8, reflecting a significant decline in its stock performance. The company has faced a 28.49% drop over the past year, alongside ongoing financial challenges, including operating losses and a negative EBIT to Interest ratio, raising concerns about its market position.

Vista Pharmaceuticals Ltd., a micro-cap pharmaceutical manufacturer with a market capitalisation of ₹56.00 crores, reported catastrophic results for Q2 FY26, with net losses widening dramatically to ₹2.59 crores—a sequential deterioration of 100.78% from Q1 FY26's loss of ₹1.29 crores and a staggering 166.99% worsening compared to Q2 FY25's loss of ₹0.97 crores. The company's operational performance has collapsed into crisis territory, with operating margins plunging to an alarming -235.62% in Q2 FY26 from -73.03% in the previous quarter.

Vista Pharmaceuticals has hit a new 52-week low of Rs. 8.25, reflecting a consistent decline over the past four days. The company has underperformed its sector and faces significant financial challenges, including decreasing net sales and operating profit, alongside concerns regarding its debt servicing capabilities.

Vista Pharmaceuticals has reached a new 52-week low of Rs. 8.25, reflecting ongoing challenges and a significant decline over the past four days. The company has underperformed its sector and is trading below key moving averages, indicating a persistent bearish trend amid financial difficulties and declining net sales.